NASDAQ$COGT
Cogent Biosciences Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Cogent Biosciences reported first quarter 2021 financial results and provided corporate updates.
Cogent Biosciences reported a net loss of $11.7 million for the first quarter of 2021, with R&D expenses at $8.2 million and G&A expenses at $4.6 million. The company ended the quarter with $230.7 million in cash and cash equivalents, expected to fund operations into 2024. Key highlights included IND clearance for a Phase 2 study of CGT9486 and the appointment of John Robinson as Chief Scientific Officer and Evan Kearns as Chief Legal Officer.
- IND was cleared for Phase 2 study of CGT9486 in Advanced Systemic Mastocytosis patients.
- John Robinson, PhD, was appointed as Chief Scientific Officer.
- Evan Kearns, JD, joined Cogent as Chief Legal Officer.
- Cogent Biosciences ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024.
Headline financials
Revenue & EPS history
Cogent Biosciences · Revenue · Quarterly
$7.03M
Forward guidance
Cogent Biosciences is on track to initiate three clinical trials of CGT9486 this year, beginning with a study in Advanced Systemic Mastocytosis (AdvSM) patients for which they recently received IND clearance from the FDA. The company continues to make great progress building a world-class R&D organization.
Tailwinds
- On track to initiate three clinical trials of CGT9486 this year
- Received IND clearance from the FDA for study in Advanced Systemic Mastocytosis (AdvSM) patients
- Building a world-class R&D organization
- Cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into 2024
- Focus on developing precision therapies for genetically defined diseases
Headwinds
- Net loss was $11.7 million for the first quarter of 2021
- Research and development expenses were $8.2 million for the first quarter of 2021
- General and administrative expenses were $4.6 million for the first quarter of 2021
- Forward-looking statements are subject to a number of material risks and uncertainties
- May not actually achieve the forecasts disclosed in forward-looking statements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+0.9%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.5%
Avg return
30 days after
65%
20 / 31 earnings
Positive
+17.8%
Q3 2018
Best reaction
-24.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -5.3% | -10.6% | |
| Q3 2025 | -4.4% | -9.1% | +140.2% | |
| Q2 2025 | -5.8% | -9.0% | +7.4% | |
| Q1 2025 | +2.7% | +4.4% | +48.4% | |
| Q4 2024 | -6.3% | +0.9% | -11.4% | |
| Q3 2024 | +0.0% | -14.4% | -19.8% | |
| Q1 2024 | +0.4% | -0.1% | +11.1% | |
| Q4 2023 | +0.7% | -2.8% | -12.4% | |
| Q3 2023 | +3.9% | +3.8% | -2.7% | |
| Q2 2023 | +7.3% | +8.8% | +9.4% | |
| Q1 2023 | -1.5% | -2.6% | -2.9% | |
| Q4 2022 | +0.7% | -5.1% | -13.7% | |
| Q3 2022 | -5.7% | -8.5% | -2.6% | |
| Q2 2022 | +9.6% | +12.1% | +32.7% | |
| Q1 2022 | -24.0% | -26.8% | -10.6% | |
| Q4 2021 | +4.5% | +28.4% | +64.6% | |
| Q3 2021 | +13.7% | +12.1% | -9.9% | |
| Q2 2021 | +5.4% | +13.4% | +3.3% | |
| Q1 2021 | +1.7% | +4.9% | +4.0% | |
| Q4 2020 | +5.9% | +5.5% | +9.0% | |
| Q3 2020 | +13.2% | +9.8% | +14.9% | |
| Q2 2020 | -11.4% | -11.0% | -8.3% | |
| Q1 2020 | +0.5% | +17.9% | +37.1% | |
| Q4 2019 | -3.1% | -15.5% | -18.6% | |
| Q3 2019 | -10.2% | -32.6% | -52.1% | |
| Q2 2019 | +4.4% | +9.3% | +9.0% | |
| Q1 2019 | +0.2% | -1.1% | -26.2% | |
| Q4 2018 | +8.1% | +5.4% | -12.3% | |
| Q3 2018 | +17.8% | +18.5% | -25.0% | |
| Q2 2018 | -5.9% | -12.8% | -27.3% | |
| Q1 2018 | +4.0% | +12.4% | +13.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro